425 related articles for article (PubMed ID: 26563392)
1. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats.
Bangphumi K; Kittiviriyakul C; Towiwat P; Rojsitthisak P; Khemawoot P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):777-785. PubMed ID: 26563392
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of curcumin diethyl disuccinate and its active metabolite curcumin in rat plasma by LC-MS/MS: Application of esterase inhibitors in the stabilization of an ester-containing prodrug.
Ratnatilaka Na Bhuket P; Niwattisaiwong N; Limpikirati P; Khemawoot P; Towiwat P; Ongpipattanakul B; Rojsitthisak P
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():301-310. PubMed ID: 27595650
[TBL] [Abstract][Full Text] [Related]
3. Chitosan-alginate nanoparticles as effective oral carriers to improve the stability, bioavailability, and cytotoxicity of curcumin diethyl disuccinate.
Sorasitthiyanukarn FN; Muangnoi C; Rojsitthisak P; Rojsitthisak P
Carbohydr Polym; 2021 Mar; 256():117426. PubMed ID: 33483016
[TBL] [Abstract][Full Text] [Related]
4. Curcumin diethyl disuccinate encapsulated in chitosan/alginate nanoparticles for improvement of its
Bhunchu S; Muangnoi C; Rojsitthisak P; Rojsitthisak P
Pharmazie; 2016 Dec; 71(12):691-700. PubMed ID: 29441997
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Fukano Y; Kawazu K
Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine.
Hemenway JN; Stella VJ
J Pharm Sci; 2010 Nov; 99(11):4565-75. PubMed ID: 20845455
[TBL] [Abstract][Full Text] [Related]
7. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Ohura K; Soejima T; Nogata R; Adachi Y; Ninomiya S; Imai T
J Pharm Sci; 2012 Sep; 101(9):3264-74. PubMed ID: 22628163
[TBL] [Abstract][Full Text] [Related]
8. Metabolic fate of poly-(lactic-co-glycolic acid)-based curcumin nanoparticles following oral administration.
Harigae T; Nakagawa K; Miyazawa T; Inoue N; Kimura F; Ikeda I; Miyazawa T
Int J Nanomedicine; 2016; 11():3009-22. PubMed ID: 27418823
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye.
Sjöquist B; Tajallaei S; Stjernschantz J
Arzneimittelforschung; 1999 Mar; 49(3):225-33. PubMed ID: 10219466
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Curcumin Bioavailability Via the Prodrug Approach: Challenges and Prospects.
Ratnatilaka Na Bhuket P; El-Magboub A; Haworth IS; Rojsitthisak P
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):341-353. PubMed ID: 27683187
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of curcumin and curcumin glucuronide in the central nervous system of mice after oral delivery of nano-curcumin.
Szymusiak M; Hu X; Leon Plata PA; Ciupinski P; Wang ZJ; Liu Y
Int J Pharm; 2016 Sep; 511(1):415-423. PubMed ID: 27426105
[TBL] [Abstract][Full Text] [Related]
13. Application of an ultra-performance liquid chromatography method with tandem mass spectrometry to pharmacokinetics, tissue distribution and excretion in the study of DAT-230, a novel tubulin-binding agent candidate, in rats.
Tang J; Zhang C; Sun J; Zhao L; Zhang W; Liu Z; Sun L; Chen X
J Pharm Biomed Anal; 2015 Jun; 110():49-57. PubMed ID: 25800882
[TBL] [Abstract][Full Text] [Related]
14. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
15. A curcumin-diglutaric acid conjugated prodrug with improved water solubility and antinociceptive properties compared to curcumin.
Muangnoi C; Jithavech P; Ratnatilaka Na Bhuket P; Supasena W; Wichitnithad W; Towiwat P; Niwattisaiwong N; Haworth IS; Rojsitthisak P
Biosci Biotechnol Biochem; 2018 Aug; 82(8):1301-1308. PubMed ID: 29678124
[TBL] [Abstract][Full Text] [Related]
16. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.
Liu G; Khanna V; Kirtane A; Grill A; Panyam J
FASEB J; 2019 Aug; 33(8):9453-9465. PubMed ID: 31136203
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity.
Perkins EJ; Abraham T
Drug Metab Dispos; 2007 Oct; 35(10):1903-9. PubMed ID: 17646281
[TBL] [Abstract][Full Text] [Related]
19. Curcumin β-D-Glucuronide Plays an Important Role to Keep High Levels of Free-Form Curcumin in the Blood.
Ozawa H; Imaizumi A; Sumi Y; Hashimoto T; Kanai M; Makino Y; Tsuda T; Takahashi N; Kakeya H
Biol Pharm Bull; 2017; 40(9):1515-1524. PubMed ID: 28867734
[TBL] [Abstract][Full Text] [Related]
20. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
